Estimating the Economic Burden of Low Health Literacy in the Blacktown Community in Sydney, Australia: A Population-Based Study

Estimating the Economic Burden of Low Health Literacy in the Blacktown Community in Sydney, Australia: A Population-Based Study
Evidence exhibits that insufficient or low well being literacy (LHL) ranges are considerably related to financial ramifications at the particular person, employer, and well being care system ranges. Therefore, this examine goals to estimate the financial burden of LHL amongst a culturally and linguistically numerous (CALD) group in Blacktown: a neighborhood authorities space (LGA) in Sydney, Australia.
This examine is a secondary evaluation of cross-sectional information from publicly accessible datasets, together with 2011 and 2016 census information and National Health Survey (NHS) information (2017-2018) from the Australian Bureau of Statistics (ABS), and figures on Disease Expenditure in Australia for 2015-2016 offered by the Australian Institute of Health and Welfare (AIHW).
This examine discovered that 20% of Blacktown residents reported low ranges of energetic engagement with well being care suppliers (Domain 6 of the Health Literacy Questionnaire (HLQ)), with 14% reporting a restricted understanding of the well being info required to take motion in direction of enhancing well being or making well being care choices (Domain 9 of the HLQ).
The general further/delta price (direct and oblique well being care prices) related to LHL in the Blacktown LGA was estimated to be between $11,785,528 and $15,432,239 in 2020. This is projected to extend to between $18,922,844 and $24,191,911 in 2030. Additionally, the further disability-adjusted life yr (DALY) worth in 2020, for all power ailments and age-groups-comprising the further prices incurred as a consequence of years of life misplaced (YLL) and years lived with incapacity (YLD)-was estimated at $414,231,335. The findings of our examine might allow policymakers to have a deeper understanding of the financial burden of LHL in phrases of its affect on the well being care system and the manufacturing economic system.

Roadmap for Managing SARS-CoV-2 and different Viruses in the Water Environment for Public Health

The water sector wants to deal with viral-related public well being points, as a result of water is a virus provider, which not solely spreads viruses (e.g., by way of ingesting water), but additionally offers details about the circulation of viruses in the group (e.g., by way of sewage). It has been broadly reported that waterborne viral pathogens are considerable, numerous, complicated, and threatening the public well being in each developed and growing international locations. Meanwhile, there may be nice potential for viral monitoring that may point out biosafety, remedy efficiency and group well being.
New developments in know-how have been rising to satisfy the rising challenges over the previous many years. Under the present coronavirus illness 2019 (COVID-19) pandemic brought on by extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the world’s consideration is directed to the pressing must sort out the most difficult public well being points associated to waterborne viruses. Based on vital evaluation of the water viral information progresses and gaps, this text gives a roadmap for managing COVID-19 and different viruses in the water environments for guaranteeing public well being.

Strategies Used to Support Peer Provision in Mental Health: A Scoping Review

The employment of peer suppliers (individuals who draw on their lived expertise of psychological well being challenges) has grown in conjunction with the elevated acceptance of restoration as a key precept in psychological well being coverage and apply. Barriers to the integration of peer suppliers in psychological well being companies have been effectively documented.
This evaluation addresses an under-explored space by consolidating methods undertaken by psychological well being organizations for the profitable implementation of peer provision. A scoping evaluation was chosen to facilitate the fast abstract and dissemination of analysis findings which might be related to policymakers and practitioners. Peer-reviewed articles and gray literature have been sourced from three databases, key peer help web sites and a hand search of the included research.
Following screening, information have been extracted from 28 research: 25 qualitative and three combined strategies research. The information have been analyzed utilizing thematic evaluation and arranged into themes. Four themes emerged from the information.
Championing of peer provision initiatives by organizational management is central to the success and sustainability of peer provision. Leadership undergirds three methods that have been mentioned: organizational preparation, recruitment, coaching and induction, and help and improvement. When peer provision is championed by organizational management, measures may be undertaken to organize the group for peer provision; recruit, practice and induce peer suppliers efficiently into the group; and help peer suppliers on the job.
 Estimating the Economic Burden of Low Health Literacy in the Blacktown Community in Sydney, Australia: A Population-Based Study

The want for well being AI ethics in medical faculty training

Health Artificial Intelligence (AI) has the potential to enhance well being care, however at the identical time, raises many moral challenges. Within the subject of well being AI ethics, the options to the questions posed by moral points equivalent to knowledgeable consent, bias, security, transparency, affected person privateness, and allocation are complicated and tough to navigate.

Lung Tissue Lysate (Normal)

1701-04 0.1 mg
EUR 260.7
Description: Lung tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Lung Tissue Lysate (Normal)

1701-05 0.1 mg
EUR 260.7
Description: Lung tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Human Adult Lung (Normal) Whole tissue lysate

HAL-1302 1 mg
EUR 628.8

Monkey (Cyno.) Normal Lung Whole tissue lysate

MCL-1194 1 mg
EUR 628.8

Monkey (Rhesus) Normal Lung Whole tissue lysate

MRL-1305 1 mg
EUR 628.8

Tissue Lysate (Normal) Human Heart

GWB-54C253 0.15 mg Ask for price

Tissue Lysate (Normal) Human Kidney

GWB-FEAC28 0.15 mg Ask for price

Human Tissue Lysate (Normal) Human Stomach

GWB-3BB116 0.15 mg Ask for price

Human Tissue Lysate (Normal) Human Prostate

GWB-326D8C 0.15 mg Ask for price

Human Tissue Lysate (Normal) Human Pancreas

GWB-8C6670 0.15 mg Ask for price

cDNA - Human Adult Normal Tissue: Lung

C1234152 40 reactions
EUR 424

Human Adult Eye whole (Normal) tissue lysate

HAL-1385 100 ug
EUR 285.6

Human Adult Skin (Normal) Whole tissue lysate

HAL-1376 1 mg
EUR 628.8

Human Lung Tissue Lysate

30R-AL006 150 ug
EUR 210
Description: Fresh tissue lysate isolated from human lung

Human Adult Heart (Normal) Whole tissue lysate

HAL-1301 1 mg
EUR 628.8

Human Adult Brain (Normal) Whole tissue lysate

HAL-1303 1 mg
EUR 628.8

Human Adult Liver (Normal) Whole tissue lysate

HAL-1304 1 mg
EUR 628.8

Human Adult Ovary (Normal) Whole tissue lysate

HAL-1316 1 mg
EUR 628.8

Human Adult Colon (Normal) Whole tissue lysate

HAL-1320 1 mg
EUR 628.8

Total RNA - Human Adult Normal Tissue: Lung

R1234152-50 50 ug
EUR 221

Human Adult Kidney (Normal) Whole tissue lysate

HAL-1305 1 mg
EUR 628.8

Human Adult Spleen (Normal) Whole tissue lysate

HAL-1306 1 mg
EUR 628.8

Human Adult Breast (Normal) Whole tissue lysate

HAL-1311 1 mg
EUR 628.8

Human Adult Testis (Normal) Whole tissue lysate

HAL-1313 1 mg
EUR 628.8

Human Adult Thymus (Normal) Whole tissue lysate

HAL-1314 1 mg
EUR 628.8

Human Adult Tonsil (Normal) Whole tissue lysate

HAL-1315 1 mg
EUR 628.8

Human Adult Uterus (Normal) Whole tissue lysate

HAL-1317 1 mg
EUR 628.8

Human Adult Rectum (Normal) Whole tissue lysate

HAL-1373 1 mg
EUR 628.8

Human Adult Retina (Normal) Whole tissue lysate

HAL-1374 1 mg
EUR 628.8

Human Adult Bladder (Normal) Whole tissue lysate

HAL-1310 1 mg
EUR 628.8

Human Adult Stomach (Normal) Whole tissue lysate

HAL-1319 1 mg
EUR 628.8

Human Adult Thyroid (Normal) Whole tissue lysate

HAL-1380 1 mg
EUR 628.8

Human Normal Adrenal Gland Whole tissue lysate

HALX-11050 1 mg
EUR 927.6

Human Adult Pancreas (Normal) Whole tissue lysate

HAL-1307 1 mg
EUR 628.8

Human Adult Placenta (Normal) Whole tissue lysate

HAL-1309 1 mg
EUR 628.8

Human Adult Prostate (Normal) Whole tissue lysate

HAL-1312 1 mg
EUR 628.8

Human Adult Appendix (Normal) Whole tissue lysate

HAL-1361 1 mg
EUR 628.8

Human Pituitary Gland (Normal) Whole tissue lysate

HALX-10141 100ug
EUR 416.4

Total Protein - Human Adult Normal Tissue: Lung

P1234152 1 mg
EUR 216

Human Lung Tissue Preparation Buffer 1: Normal Lung Fibroblasts

9-80081 1 x 100 ml Ask for price

Frozen Tissue Section - Human Adult Normal: Lung

T1234152 5 slides
EUR 377

Colon Tissue Lysate (Normal)

1715-01 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-02 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-03 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-04 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-05 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-06 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-07 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-08 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-10 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-11 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-12 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-13 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-14 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-15 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-16 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-17 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-19 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-20 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-21 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Colon Tissue Lysate (Normal)

1715-22 0.1 mg
EUR 260.7
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Liver Tissue Lysate (Normal)

1718-01 0.1 mg
EUR 260.7
Description: Liver tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Liver Tissue Lysate (Normal)

1718-02 0.1 mg
EUR 260.7
Description: Liver tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Brain Tissue Lysate (Normal)

1731-01 0.1 mg
EUR 260.7
Description: Brain tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Brain Tissue Lysate (Normal)

1731-02 0.1 mg
EUR 260.7
Description: Brain tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Brain Tissue Lysate (Normal)

1731-03 0.1 mg
EUR 260.7
Description: Brain tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Paraffin Tissue Section - Human Adult Normal: Lung

T2234152 5 slides
EUR 204

Membrane Protein - Human Adult Normal Tissue: Lung

P3234152 0.1 mg
EUR 311

Human Adult Lymph Node (Normal) Whole tissue lysate

HAL-1369 1 mg
EUR 927.6

Kidney Tissue Lysate (Normal)

1706-02 0.1 mg
EUR 260.7
Description: Kidney tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Normal)

1706-03 0.1 mg
EUR 260.7
Description: Kidney tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Normal)

1706-04 0.1 mg
EUR 260.7
Description: Kidney tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Kidney Tissue Lysate (Normal)

1706-05 0.1 mg
EUR 260.7
Description: Kidney tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-01 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-03 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-04 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-05 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-06 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-07 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-08 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-10 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-11 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Normal)

1710-12 0.1 mg
EUR 260.7
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Cervix Tissue Lysate (Normal)

1746-01 0.1 mg
EUR 260.7
Description: Cervix tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Cervix Tissue Lysate (Normal)

1746-02 0.1 mg
EUR 260.7
Description: Cervix tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Cervix Tissue Lysate (Normal)

1746-03 0.1 mg
EUR 260.7
Description: Cervix tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Human Adult Spinal Cord (Normal) Whole tissue lysate

HAL-1377 1 mg
EUR 927.6

Stomach Tissue Lysate (Normal)

1717-01 0.1 mg
EUR 260.7
Description: Stomach tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Bladder Tissue Lysate (Normal)

1721-01 0.1 mg
EUR 260.7
Description: Bladder tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

FFPE Total RNA - Human Adult Normal Tissue: Lung

R2234152 1 ug
EUR 744

Pancreas Tissue Lysate (Normal)

1736-02 0.1 mg
EUR 260.7
Description: Pancreas tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Pancreas Tissue Lysate (Normal)

1736-05 0.1 mg
EUR 260.7
Description: Pancreas tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Lung Tissue Slide (Normal)

10-101-10um 10 um
EUR 241.8

Lung Tissue Slide (Normal)

10-101-4um 4 um
EUR 216.6

Normal lung tissue array

LC725 each
EUR 270
Description: Normal lung tissue array, 24 cases/72 cores, replacing BN04011

Normal lung tissue array

LCN241 each
EUR 114
Description: Normal lung tissue array, 24 cases/24 cores

FFPE Genomic DNA - Human Adult Normal Tissue: Lung

D2234152 2 ug
EUR 787

Human Lung Fetal Tissue Lysate

IHULGFSTL100UG each
EUR 541
Description: Human Lung Fetal Tissue Lysate

Human Adult Salivary (Normal) Gland Whole tissue lysate

HAL-20103 1 mg
EUR 927.6

Human Adult Small Intestine (Normal) Whole tissue lysate

HAL-1308 1 mg
EUR 628.8

Human Adult Skeletal Muscle (Normal) Whole tissue lysate

HAL-1375 1 mg
EUR 628.8

Human Lupus Lung Tissue Lysate

IHULGLUPPTL100UG each
EUR 1413
Description: Human Lupus Lung Tissue Lysate

Human Diabetes Lung Tissue Lysate

IHULGDIBTL100UG each
EUR 1413
Description: Human Diabetes Lung Tissue Lysate

Lung cancer tissue array with adjacent normal lung tissue

LC813a each
EUR 270
Description: Lung cancer tissue array with adjacent normal lung tissue, including TNM, clinical stage and pathology grade, 78 cases/80 cores, replaced by LC813b

Liver Tissue Lysate Normal Rabbit

GWB-369DB5 0.15 mg Ask for price

Lung cancer and normal lung tissue array

LC482 each
EUR 198
Description: Lung cancer and normal lung tissue array, including TNM, clinical stage and pathology grade, 24 cases/48 cores

Lung cancer and normal lung tissue array

LC811a each
EUR 270
Description: Lung cancer and normal lung tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 core

cDNA - Human Adult Normal Tissue: Lung: Left Lower Lobe

C1234155 40 reactions
EUR 424

cDNA - Human Adult Normal Tissue: Lung: Left Upper Lobe

C1234156 40 reactions
EUR 424

cDNA - Rat Normal Tissue: Lung

C1434152 40 reactions
EUR 424

cDNA - Dog Normal Tissue: Lung

C1734152 40 reactions
EUR 424

Total RNA - Human Adult Normal Tissue: Lung, 0 shipping

ATR1234152-50 50 ug
EUR 241

cDNA - Human Adult Normal Tissue: Lung: Right Lower Lobe

C1234157 40 reactions
EUR 424

cDNA - Human Adult Normal Tissue: Lung: Right Upper Lobe

C1234159 40 reactions
EUR 424

cDNA - Human Adult Normal Tissue: Lung: Right Middle Lobe

C1234158 40 reactions
EUR 424

cDNA - Mouse Normal Tissue: Lung

C1334152 40 reactions
EUR 424

Normal lung tissue with liver tissue array

LCN981 each
EUR 354
Description: Normal lung tissue with liver tissue array, 49 cases/98 cores (1.5mm)

Human WI-38 (Lung Fibroblast, normal) lysate

HCL-1226 100ug
EUR 285.6

Rat Tissue Lysate Normal Eye Retina

GWB-792900 0.15 mg Ask for price

Total RNA - Human Adult Normal Tissue 5 Donor Pool: Lung

R1234152-P 50 ug
EUR 443

Lung Tissue Slides, Normal Human Paraffin Sections, 5 slides/pack

TS-H5015 -
EUR 145

Total RNA - Human Adult Normal Tissue: Lung: Left Lower Lobe

R1234155-50 50 ug
EUR 221

Total RNA - Human Adult Normal Tissue: Lung: Left Upper Lobe

R1234156-50 50 ug
EUR 221

Human Liver Cirrhosis Lung Tissue Lysate

IHULGCIRTL100UG each
EUR 1413
Description: Human Liver Cirrhosis Lung Tissue Lysate

Total RNA - Human Adult Normal Tissue: Lung: Right Lower Lobe

R1234157-50 50 ug
EUR 221

Total RNA - Human Adult Normal Tissue: Lung: Right Upper Lobe

R1234159-50 50 ug
EUR 221

Lung tuberculosis tissue array with normal tissue

LC1007 each
EUR 306
Description: Lung tuberculosis tissue array with normal tissue, 48 cases/100 cores

Total RNA - Human Adult Normal Tissue: Lung: Right Middle Lobe

R1234158-50 50 ug
EUR 221

Total RNA - Rat Normal Tissue: Lung

R1434152-50 50 ug
EUR 156

Matched Pair - DNA - Human Primary Tumor and Normal Tissue: Lung

D8235152-PP-10 2x10 ug
EUR 478

Rat normal lung test tissue array

TR041 each
EUR 48
Description: Rat normal lung test tissue array, 6 cases/24 cores

Matched Pair - cDNA - Human Primary Tumor and Normal Tissue: Lung

C8235152-PP 10 reactions x2
EUR 583

Total Protein - Human Adult Normal Tissue: Lung: Left Lower Lobe

P1234155 1 mg
EUR 216

Total Protein - Human Adult Normal Tissue: Lung: Left Upper Lobe

P1234156 1 mg
EUR 216

Genomic DNA - Rat Normal Tissue: Lung

D1434152 100 ug
EUR 329

Total RNA - Mouse Normal Tissue: Lung

R1334152-50 50 ug
EUR 156

Total Protein - Human Adult Normal Tissue: Lung: Right Lower Lobe

P1234157 1 mg
EUR 216

Total Protein - Human Adult Normal Tissue: Lung: Right Upper Lobe

P1234159 1 mg
EUR 216

Lung cancer and normal tissue array

LC722 each
EUR 306
Description: Lung cancer and normal tissue array, with TNM and grade data, 24 cases/72 cores

Rat Tissue Lysate Kidney Medulla Normal

GWB-F5DEBF 0.15 mg Ask for price

Total Protein - Human Adult Normal Tissue: Lung: Right Middle Lobe

P1234158 1 mg
EUR 216

Genomic DNA - Mouse Normal Tissue: Lung

D1334152 100 ug
EUR 329

Monkey (Cyno.) Normal Adipose tissue lysate

MCL-1159 1 mg
EUR 927.6

Membrane Protein - Human Adult Normal Tissue: Lung: Left Upper Lobe

P3234156 0.1 mg
EUR 311

Lung adenocarcinoma tissue array with normal lung tissue (2015 WHO classification)

BC04119b each
EUR 270
Description: Lung adenocarcinoma tissue array with normal lung tissue (2015 WHO classification), including pathology grade, TNM and clinical stage,30 cases/40 cores, replacing BC04119a

cDNA - Monkey (Rhesus) Normal Tissue: Lung

C1534152 40 reactions
EUR 481

Monkey (Rhesus) Normal Adipose tissue lysate

MRL-1266 1 mg
EUR 927.6

Total Protein - Mouse Normal Tissue: Lung

P1334152 1 mg
EUR 216

Genomic DNA - Human Adult Normal Tissue: Lung, from a single donor

D1234152 100 ug
EUR 329

Lung non-small cell carcinoma NSCLC tissue array with normal lung tissue

LC10011b each
EUR 306
Description: Lung non-small cell carcinoma NSCLC tissue array with normal lung tissue, including TNM, clinical stage and pathology grade, 50 cases/100 cores, replacing LC10011a

Universal Protein Lysate: Human Normal Tissues

P4234565 4x0.5 mg
EUR 466

Universal Protein Lysate: Human Normal Tissues

P4234565-1 2x0.5 mg
EUR 311

Matched Pair - Total RNA - Human Primary Tumor and Normal Tissue: Lung

R8235152-PP-10 2x10 ug
EUR 500

cDNA - Monkey (Cynomolgus) Normal Tissue: Lung

C1534152-Cy 40 reactions
EUR 481

Lung cancer tissue array with normal tissue as control

LC1021 each
EUR 306
Description: Lung cancer tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, 102 cases/102 cores

Lung cancer tissue array with normal tissue as control

LC807b each
EUR 306
Description: Lung cancer tissue array with normal tissue as control, including TNM, clinical stage and pathology grade, cases/ cores,replacing LC807a

Monkey (Cyno.) Normal Skin Whole tissue lysate

MCL-1204 1 mg
EUR 927.6

Lung non-small cell carcinoma NSCLC tissue array with cancer adjacent lung tissue and normal lung tissue

LC10012b each
EUR 306
Description: Lung non-small cell carcinoma NSCLC tissue array with cancer adjacent lung tissue and normal lung tissue, including TNM, clinical stage and pathology grade, 50 cases/100 cores, replaced by LC10012c

Monkey (Cyno.) Normal Colon Whole tissue lysate

MCL-1179 1 mg
EUR 628.8

Monkey (Cyno.) Normal Liver Whole tissue lysate

MCL-1191 1 mg
EUR 628.8

Monkey (Cyno.) Normal Brain Whole tissue lysate

MCL-1272 1 mg
EUR 628.8

Monkey (Cyno.) Normal Breast Whole tissue lysate

MCL-1177 1 mg
EUR 927.6

Monkey (Cyno.) Normal Kidney Whole tissue lysate

MCL-1190 1 mg
EUR 628.8

Monkey (Cyno.) Normal Rectum Whole tissue lysate

MCL-1203 1 mg
EUR 927.6

Monkey (Cyno.) Normal Spleen Whole tissue lysate

MCL-1209 1 mg
EUR 628.8

Monkey (Cyno.) Normal Testis Whole tissue lysate

MCL-1215 1 mg
EUR 927.6

Monkey (Cyno.) Normal Thymus Whole tissue lysate

MCL-1217 1 mg
EUR 927.6

Monkey (Cyno.) Normal Uterus Whole tissue lysate

MCL-1222 1 mg
EUR 927.6

Monkey (Rhesus) Normal Skin Whole tissue lysate

MRL-1315 1 mg
EUR 927.6

Monkey (Cyno.) Normal Bladder Whole tissue lysate

MCL-1162 1 mg
EUR 927.6

Monkey (Cyno.) Normal Stomach Whole tissue lysate

MCL-1210 1 mg
EUR 628.8

Monkey (Cyno.) Normal Thyroid Whole tissue lysate

MCL-1218 1 mg
EUR 927.6

Monkey (Rhesus) Normal Brain Whole tissue lysate

MRL-1272 1 mg
EUR 628.8

Monkey (Rhesus) Normal Colon Whole tissue lysate

MRL-1288 1 mg
EUR 628.8

Monkey (Rhesus) Normal Heart Whole tissue lysate

MRL-1299 1 mg
EUR 927.6

Monkey (Rhesus) Normal Liver Whole tissue lysate

MRL-1302 1 mg
EUR 628.8

Lung small cell cancer array and normal lung tissue array

LC10010d each
EUR 306
Description: Lung small cell cancer array and normal lung tissue array, including TNM and clinical stage, 50 cases/100 cores (1.0), replacing LC10010c

Matched Pair (Normal and Carcinoma) Human Lung Tissue Array (5 slides/pk)

TAS-1002 1 pk
EUR 343.2

Human Lung Tissue Preparation Buffer 3: Normal Pulmonary Artery Fibroblasts

9-80083 1 x 100 ml Ask for price

Rat Lung Tissue Preparation Buffer 1: Normal Lung Fibroblasts

9-80271 1 x 100 ml Ask for price

Monkey (Cyno.) Normal Appendix Whole tissue lysate

MCL-1161 1 mg
EUR 927.6
The growing quantity of information, market forces, and altering panorama of well being care counsel that medical college students could also be confronted with a office in which understanding easy methods to safely and successfully work together with well being AIs shall be important. Here we argue that there’s a want to show well being AI ethics in medical faculties. Real occasions in well being AI already pose moral challenges to the medical group. We focus on key moral points requiring medical faculty training and counsel that case research based mostly on latest real-life examples are helpful instruments to show the moral points raised by well being AIs.

Fatima Burgol

Medicine student, liking to read publications and Ivd improvements adapted to my country.

Leave a Reply

Your email address will not be published. Required fields are marked *